203 related articles for article (PubMed ID: 20670353)
1. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15.
Gong W; Xiao W; Hu M; Weng X; Qian L; Pan X; Ji M
Tissue Antigens; 2010 Dec; 76(6):467-75. PubMed ID: 20670353
[TBL] [Abstract][Full Text] [Related]
2. Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21.
Jiang B; Wu X; Li XN; Yang X; Zhou Y; Yan H; Wei AH; Yan W
Cell Immunol; 2014 Jul; 290(1):10-20. PubMed ID: 24859012
[TBL] [Abstract][Full Text] [Related]
3. [Expansion of human natural killer cells ex vivo].
Huang QS; Li Q; Huang Y; Shang P; Zhang MJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Dec; 24(12):1167-9. PubMed ID: 19068202
[TBL] [Abstract][Full Text] [Related]
4. Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo.
Gong W; Xiao W; Qian L; Gong C; Hu M; Pan X; Ji M
Cell Mol Immunol; 2010 Nov; 7(6):477-84. PubMed ID: 20871627
[TBL] [Abstract][Full Text] [Related]
5. Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression.
Nishimura M; Mitsunaga S; Akaza T; Mitomi Y; Tadokoro K; Juji T
Immunology; 1994 Sep; 83(1):75-80. PubMed ID: 7821970
[TBL] [Abstract][Full Text] [Related]
6. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
[TBL] [Abstract][Full Text] [Related]
9. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.
Dowell AC; Oldham KA; Bhatt RI; Lee SP; Searle PF
Cancer Immunol Immunother; 2012 May; 61(5):615-28. PubMed ID: 22021067
[TBL] [Abstract][Full Text] [Related]
10. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells.
Baek HJ; Kim JS; Yoon M; Lee JJ; Shin MG; Ryang DW; Kook H; Kim SK; Cho D
Anticancer Res; 2013 May; 33(5):2011-9. PubMed ID: 23645750
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
13. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
14. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
Lu ZY; Condomines M; Tarte K; Nadal L; Delteil MC; Rossi JF; Ferrand C; Klein B
Exp Hematol; 2007 Mar; 35(3):443-53. PubMed ID: 17309825
[TBL] [Abstract][Full Text] [Related]
15. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function.
Lin SJ; Kuo ML
Cytotherapy; 2008; 10(4):397-405. PubMed ID: 18574772
[TBL] [Abstract][Full Text] [Related]
16. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U
J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation.
Zhang C; Zhang J; Niu J; Zhang J; Tian Z
Cytokine; 2008 Apr; 42(1):128-36. PubMed ID: 18280748
[TBL] [Abstract][Full Text] [Related]
18. Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor.
Balsamo M; Vermi W; Parodi M; Pietra G; Manzini C; Queirolo P; Lonardi S; Augugliaro R; Moretta A; Facchetti F; Moretta L; Mingari MC; Vitale M
Eur J Immunol; 2012 Jul; 42(7):1833-42. PubMed ID: 22585684
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-15 activated bovine natural killer cells express CD69 and produce interferon-γ.
Lund H; Boysen P; Dean GA; Davis WC; Park KT; Storset AK
Vet Immunol Immunopathol; 2012 Nov; 150(1-2):79-89. PubMed ID: 23021353
[TBL] [Abstract][Full Text] [Related]
20. MHC class I chain-related molecules induced on monocytes by IFN-gamma promote NK cell activation.
Wang H; Ruan Z; Wang Y; Han J; Fu X; Zhao T; Yang D; Xu W; Yang Z; Wang L; Chen Y; Wu Y
Mol Immunol; 2008 Mar; 45(6):1548-56. PubMed ID: 18062910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
